The Diovan scandal in Japan; don't let bygones be bygones

J Hum Hypertens. 2022 May;36(5):500-501. doi: 10.1038/s41371-022-00680-2. Epub 2022 Mar 29.

Authors

Nanami Murata¹, Akihiko Ozaki^{2

3}, Anju Murayama², Toyoaki Sawano⁴, Tetsuya Tanimoto^{2

5}

Affiliations

¹ Medical Governance Research Institute, Minato-ku, Tokyo, Japan. murata773.2020@gmail.com.
² Medical Governance Research Institute, Minato-ku, Tokyo, Japan.
³ Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan.
⁴ Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan.
⁵ Department of Internal Medicine, Navitas Clinic Kawasaki, Tokyo, Japan.

PMID: 35351964
DOI: 10.1038/s41371-022-00680-2

No abstract available

Publication types

Letter

MeSH terms

Humans
Japan
Valsartan*

Substances

Valsartan